[EBS] Emergent Biosolutions, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NYSE

The data is delayed by 15 minutes.


Price: 33.6 Change: 0.1 (0.3%)
Ext. hours: Change: 0 (0%)

chart EBS

Refresh chart

Strongest Trends Summary For EBS

EBS is in the medium-term up 20% above S&P in 1 year. In the long-term up 79% above S&P in 2 years and up 94% in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Emergent BioSolutions Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes specialized products for use in defense and commercial markets in the United States and internationally. The company operates in two segments, Biodefense and Biosciences. The Biodefense segment markets BioThrax, an FDA approved vaccine for the prevention of anthrax disease; BAT (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-Equine) for the treatment of suspected or documented exposure to botulinum neurotoxin A, B, C, D, E, F, or G; Vaccinia Immune Globulin Intravenous for counteracting complications associated with the smallpox vaccine; and RSDL (decontamination lotion) to remove and/or neutralize chemical warfare agents from the skin. This segment is also developing Anthrax Immune Globulin Intravenous to treat toxemia associated with inhalational anthrax; NuThrax, an anthrax vaccine in Phase II clinical trials, which is based on BioThrax combined with CPG 7909, an adjuvant licensed from Pfizer Inc.; an

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -42.32% Sales Growth - Q/Q-57% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA3.86% ROE6.59% ROI4.26%
Current Ratio5.05 Quick Ratio4.03 Long Term Debt/Equity0.77 Debt Ratio0.15
Gross Margin74.31% Operating Margin12% Net Profit Margin7.71% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities11 M Cash From Investing Activities-9.08 M Cash From Operating Activities-65.87 M Gross Profit44.88 M
Net Profit-21.52 M Operating Profit-28.31 M Total Assets917.85 M Total Current Assets405.81 M
Total Current Liabilities80.3 M Total Debt251 M Total Liabilities379.97 M Total Revenue63.63 M
Technical Data
High 52 week73.24 Low 52 week42.42 Last close58.59 Last change-3.73%
RSI17.18 Average true range3.15 Beta0.82 Volume333.02 K
Simple moving average 20 days-12.99% Simple moving average 50 days-10.21% Simple moving average 200 days1.34%
Performance Data
Performance Week-9.28% Performance Month-17.79% Performance Quart-11.63% Performance Half9.25%
Performance Year26.93% Performance Year-to-date26.08% Volatility daily2.45% Volatility weekly5.49%
Volatility monthly11.25% Volatility yearly38.96% Relative Volume180.22% Average Volume401.43 K
New High New Low


2019-03-19 06:30:00 | Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

2019-03-14 11:21:02 | Life Sciences Pa. reveals awards for its top CEO, top products and deal of the year

2019-03-11 07:15:11 | The Emergent BioSolutions NYSE:EBS Share Price Has Gained 111%, So Why Not Pay It Some Attention?

2019-02-28 16:45:43 | Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents

2019-02-25 16:20:00 | Emergent BioSolutions Looks to Break $1 Billion

2019-02-22 21:48:03 | Emergent BioSolutions Inc EBS Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-02-22 15:42:04 | Edited Transcript of EBS earnings conference call or presentation 21-Feb-19 10:00pm GMT

2019-02-22 11:26:04 | Emergent EBS Q4 Earnings, Revenues Surpass Estimates

2019-02-21 21:26:08 | Emergent Biosolutions Inc EBS Q4 2018 Earnings Conference Call Transcript

2019-02-21 19:55:12 | Emergent Biosolutions EBS Q4 Earnings and Revenues Surpass Estimates

2019-02-21 19:08:34 | Emergent Biosolutions: 4Q Earnings Snapshot

2019-02-21 16:05:00 | Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results

2019-02-15 07:50:00 | Factors of Influence in 2019, Key Indicators and Opportunity within CVS Health, Solaris Oilfield Infrastructure, SK Telecom Co., Energizer, Emergent Biosolutions, and Quad Graphics — New Research Emphasizes Economic Growth

2019-02-14 11:07:38 | Who Has Been Selling Emergent BioSolutions Inc. NYSE:EBS Shares?

2019-02-14 10:31:03 | Earnings Preview: Emergent Biosolutions EBS Q4 Earnings Expected to Decline

2019-02-12 06:30:00 | Emergent BioSolutions Announces Appointment of Seamus Mulligan to its Board of Directors

2019-02-08 08:02:25 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-02-07 09:35:17 | Emergent BioSolutions to Release Fourth Quarter and Full Year 2018 Financial Results and Conduct a Conference Call on February 21, 2019

2019-01-24 07:00:00 | Emergent BioSolutions Announces Appointment of Robert G. Kramer, Sr. to Its Board of Directors

2019-01-22 14:18:48 | An extended shutdown could bode poorly for local biotechs

2019-01-22 08:06:53 | See what the IHS Markit Score report has to say about Liberty Global PLC.

2019-01-15 08:05:37 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-01-09 19:02:11 | MoCo economic development officials plan satellite office in Boston

2019-01-09 08:05:42 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2019-01-08 17:20:10 | Emergent EBS Up on '19 View, Posts Preliminary '18 Results

2019-01-07 11:41:40 | Emergent BioSolutions CEO to step down

2019-01-07 10:09:03 | Emergent EBS CEO Abdun Nabi to Retire, Kramer to Succeed

2019-01-07 06:30:00 | Emergent BioSolutions Announces Preliminary 2018 Financial Results and Provides 2019 Financial Forecast

2019-01-04 10:56:42 | Our Take On Emergent BioSolutions Inc.’s NYSE:EBS CEO Salary

2019-01-04 07:00:00 | Emergent BioSolutions Announces Daniel J. Abdun-Nabi to Retire as CEO; Robert G. Kramer, Sr. to Become President and CEO

2018-12-31 08:10:01 | Emergent EBS Files Application for Emergency Use of NuThrax

2018-12-28 09:01:30 | Emergent BioSolutions Announces Submission to FDA of Application Covering Emergency Use Authorization for NuThrax™

2018-12-19 22:35:13 | Hedge Funds Are Buying Emergent Biosolutions Inc EBS

2018-12-18 16:56:34 | U.S. FDA panel backs prescribing opioid overdose reversal drug along with painkillers

2018-12-17 16:10:00 | Emergent BioSolutions Receives Health Canada Approval of BioThrax® Anthrax Vaccine Adsorbed

2018-12-11 08:05:30 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2018-12-08 08:05:17 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2018-12-05 12:22:55 | Read This Before Judging Emergent BioSolutions Inc’s NYSE:EBS ROE

2018-12-04 08:15:00 | Detailed Research: Economic Perspectives on United Technologies, Walmart, Invitae, Emergent Biosolutions, U.S. Physical Therapy, and Amdocs — What Drives Growth in Today's Competitive Landscape

2018-12-01 09:31:02 | Emergent Biosolutions EBS Up 14.1% Since Last Earnings Report: Can It Continue?

2018-11-29 08:04:11 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2018-11-22 08:02:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2018-11-20 09:10:02 | Emergent's EBS Zika Vaccine Candidate Meets Study Endpoint

2018-11-19 17:05:53 | Emergent-Valneva Zika vaccine clears early trial

2018-11-19 16:22:22 | Emergent BioSolutions and Valneva Report Positive Phase 1 Results for Their Vaccine Candidate Against the Zika Virus


2018-11-15 08:02:19 | See what the IHS Markit Score report has to say about Emergent Biosolutions Inc.

2018-11-06 15:39:00 | Emergent BioSolutions Nabs Its Acquisition Times 2

2018-11-06 07:00:00 | Emergent BioSolutions to Participate in Series of Near-Term Investor Conferences

2018-11-02 12:54:04 | Emergent EBS Q3 Earnings and Revenues Fall Shy of Estimates